Clinical trials: Adolescent Behavior
- Condition Adolescent Behavior
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17
- Trial name
- NCT00152009
- Testing
- SPD503 (Guanfacine hydrochloride) (2 mg), SPD503 (3 mg), SPD503 (4 mg)
- Volunteers
- 345 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, tolerability and effects of Osmotic Release Oral System (OROS) methylphenidate hydrochloride (HCl) on learning skill changes in Korean participants with Attention-Deficit…
- Trial name
- NCT01060150
- Testing
- OROS Methylphenidate HCl
- Volunteers
- 115 people
- Sponsor
- Janssen Korea, Ltd., Korea
Underage Drinking, Alcohol Use, Underage
REAL Parenting Alcohol and Substance Use App
High school students' alcohol, nicotine, and marijuana use are major public health problems. Among the many consequences of these risky behaviors are impaired driving and impaired passenger fatalities as well as increased health…
- Trial name
- RP (NCT03932097)
- Testing
- REAL Parenting, Active Control Materials
- Where
- United States
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- Real Prevention, LLC
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01552902
- Testing
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride
- Where
- 95 sites in United States, Canada and 3 more
- Volunteers
- 549 people
- Sponsor
- Shire
Attention-Deficit/Hyperactivity Disorder
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over…
- Trial name
- RE-DAX (NCT04507204)
- Testing
- Adhansia XR, Concerta
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Purdue Pharma LP
Attention Deficit and Disruptive Behavior Disorders
A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
The purpose of this study is to assess the efficacy and safety of risperidone as maintenance therapy to prevent symptoms of relapse in children and adolescents with conduct and other disruptive behavior disorders, who initially…
- Trial name
- NCT00236444
- Testing
- risperidone
- Volunteers
- 375 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ADHD
Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo in adolescent subjects (13-17 years of age inclusive) with ADHD in the analog classroom setting based on the Permanent Product Measure…
- Trial name
- NCT01274221
- Testing
- SPD489
- Where
- 6 sites in United States
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in…
- Trial name
- NCT00723190
- Testing
- CLONICEL (Clonidine HCl sustained release)
- Where
- 27 sites in United States
- Volunteers
- 303 people
- Sponsor
- Shionogi
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371734
- Testing
- Desvenlafaxine Succinate Sustained-Release
- Where
- 42 sites in United States, Chile and 1 more
- Volunteers
- 363 people
- Sponsor
- Pfizer
Conduct Disorder
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior.
- Trial name
- NCT00154362
- Testing
- Oxcarbazepine
- Volunteers
- 50 people
- Sponsor
- Novartis
Depression, Anxiety
Feasibility and Acceptability of W-GenZD vs CBT-light Teletherapy for Adolescents Seeking Mental Health Services
The primary aim of this study is to determine the feasibility and acceptability of the W-GenZD mobile application among a group of adolescents and who have screened and triaged into low-intensity treatment within the Children's…
- Trial name
- NCT05372913
- Testing
- Woebot for Adolescents (W-GenZD) Mobile Application, CBT-Lite Teletherapy Group
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Woebot Health
Obsessive-Compulsive Disorder
Child and Adolescent OCD Outcomes From Exposure and Response Prevention Video Teletherapy Treatment
This is a naturalistic, observational study of children and adolescents with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy.
- Trial name
- NCT06466447
- Testing
- Exposure and response prevention therapy
- Where
- United States
- Volunteers
- 2,173 people
- Sponsor
- NOCD
Attention Deficit Hyperactivity Disorder
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02450890
- Where
- 4 sites in Taiwan
- Volunteers
- 114 people
- Sponsor
- Orient Pharma Co., Ltd.
Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.
- Trial name
- NCT00191048
- Testing
- Atomoxetine
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Eli Lilly and Company
Autism Spectrum Disorder, Social Communication Disorder
To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD
The purpose of this study is to demonstrate the superiority of the treatment of cognitive therapy software 'NDTx-01' compared to TAU (Treatment-As-Usual).
- Trial name
- NCT06446193
- Testing
- NDTx-01, TAU
- Where
- 5 sites in South Korea
- Volunteers
- 86 people
- Sponsor
- Neudive Inc.
ADHD
Efficacy and Safety of SPD503 in Combination With Psychostimulants
The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal…
- Trial name
- NCT00734578
- Testing
- SPD503-AM, SPD503-PM
- Where
- 61 sites in United States
- Volunteers
- 461 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD
This study will evaluate safety and efficacy of d-Amphetamine Transdermal System for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents.
- Trial name
- NCT01711021
- Testing
- d-Amphetamine Transdermal Patch
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Noven Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder, Cannabis Abuse
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.
- Trial name
- PEACE (NCT00687609)
- Testing
- Atomoxetine
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Attentin® in Children and Adolescents With ADHD - A Non-interventional Study
The practicality of most ADHD medications is not or only moderately examined under long term routine conditions. Therefore, in this multi-centre, multi-national prospective non-interventional study, a recommended follow-up time…
- Trial name
- Attention (NCT02801604)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Oppositional Defiant Disorder, Conduct Disorder
Integrated Smart Speaker Promoting Positive Parenting Among Caregivers of Youth With Challenging Behaviors
This project will develop and evaluate the feasibility of an integrated smart speaker and mobile/web-based application, "FamilyNet" (FN) to assist parents in implementing empirically supported behavioral parenting strategies to…
- Trial name
- FamilyNet (NCT05535387)
- Testing
- FamilyNet smart speaker/mobile application
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.